文献速递瓣膜外科主动脉外科

主动脉根部同种移植物再手术

Aortic root allograft reoperations.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-02-15

该研究回顾了1987年1月至2020年7月在克利夫兰诊所进行的602例患者共632次同种移植物相关再手术,比较2006年前后两个时代及不同手术方式的结果,发现再手术死亡率低,根治性移植物取出与仅行瓣中瓣置换结果相似但可植入更大尺寸瓣膜。

要点

  • 再手术指征以结构性瓣膜衰败为主(79%),感染性心内膜炎占14%。
  • 根治性移植物取出术后死亡率2.4%,仅行瓣中瓣置换为4.0%,同种移植物保留为17%。
  • 根治性取出组植入瓣膜尺寸中位数25 mm,大于仅行瓣中瓣置换组的23 mm。

核心结论

  • 主动脉根部同种移植物再手术技术难度大,但死亡率和并发症发生率低。
  • 根治性移植物取出与仅行瓣中瓣置换结果相似,且允许植入更大尺寸的人工瓣膜。
  • 随着同种移植物再手术经验增加,结果优良,因此再手术风险不应阻止外科医生在侵袭性主动脉瓣感染性心内膜炎等适应证中使用同种移植物。

研究设计与样本

  • 回顾性研究,纳入1987年1月至2020年7月在克利夫兰诊所接受同种移植物相关再手术的602例患者,共632次再手术。
  • 按时代分为早期(2006年前,144例)和近期(2006年至今,488例)。
  • 再手术指征包括结构性瓣膜衰败502例(79%)、感染性心内膜炎90例(14%)、非结构性瓣膜衰败/非感染性心内膜炎40例(6.3%)。
  • 再手术技术包括根治性同种移植物取出372例(59%)、仅行瓣中瓣置换248例(39%)、同种移植物保留12例(1.9%)。

主要发现

  • 按指征划分的手术死亡率:结构性瓣膜衰败为2.2%(n=11),感染性心内膜炎为7.8%(n=7),非结构性瓣膜衰败/非感染性心内膜炎为7.5%(n=3)。
  • 按手术方式划分的手术死亡率:根治性取出为2.4%(n=9),仅行瓣中瓣置换为4.0%(n=10),同种移植物保留为17%(n=2)。
  • 根治性取出组手术不良事件发生率为4.9%(n=18),仅行瓣中瓣置换组为2.8%(n=7)(P=0.2)。
  • 根治性取出组植入瓣膜尺寸中位数为25 mm,仅行瓣中瓣置换组为23 mm。

临床怎么用

  • 作者认为,随着同种移植物再手术经验增加,结果优良,再手术风险不应阻止外科医生在侵袭性主动脉瓣感染性心内膜炎等适应证中使用同种移植物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate outcomes after aortic root allograft reoperation, identify risk factors for morbidity and mortality, and describe practice evolution since publication of our 2006 allograft reoperation study. METHODS: From January 1987 to July 2020, 602 patients underwent 632 allograft-related reoperations at Cleveland Clinic: 144 before 2006 (early era, which suggested radical explant was superior to aortic-valve-replacement-within-allograft [AVR-only]), and 488 from 2006 to present (recent era). Indications for reoperation were structural valve deterioration in 502 (79%), infective endocarditis in 90 (14%), and nonstructural valve deterioration/noninfective endocarditis in 40 (6.3%). Reoperative techniques included radical allograft explant in 372 (59%), AVR-only in 248 (39%), and allograft preservation in 12 (1.9%). Perioperative events and survival were assessed among indications, techniques, and eras. RESULTS: Operative mortality by indication was 2.2% (n = 11) for structural valve deterioration, 7.8% (n = 7) in those with infective endocarditis, and 7.5% (n = 3) for nonstructural valve deterioration/noninfective endocarditis, and by surgical approach 2.4% (n = 9) after radical explant, 4.0% (n = 10) for AVR-only, and 17% (n = 2) for allograft preservation. Operative adverse events occurred in 4.9% (n = 18) of radical explants and 2.8% (n = 7) of AVR-only procedures (P = .2). Patients undergoing radical explants received larger valves than those undergoing AVR-only (median, 25 vs 23 mm). CONCLUSIONS: Aortic root allograft reoperations present a technical challenge but can be performed with low mortality and morbidity. Radical explant offers outcomes similar to AVR-only while allowing for implant of larger prostheses. Increasing experience with allograft reoperations has permitted excellent outcomes; thus, risk of reoperation should not dissuade surgeons from using allografts for invasive aortic valve infective endocarditis and other indications.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Witten JC, Umana-Pizano J, Houghtaling PL, et al. Aortic root allograft reoperations. J Thorac Cardiovasc Surg. 2023. PMID: 37074251. doi:10.1016/j.jtcvs.2023.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。